Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for Phase I:~* Adult lung transplant recipients age 18 or older~* At risk for CMV (donor or recipient serology must be positive for CMV)~* Adequate hematological and renal function,~* On intravenous (IV) ganciclovir within 24 hours of surgery~* Agreement to use effective methods of contraception~* Negative pregnancy~* Tolerate oral medications within 2 weeks of transplant~* Negative baseline CMV PCR~* Able to understand and sign the informed consent~Exclusion Criteria for Phase 1:~* Repeat transplantation~* Mechanical ventilation at study entry~* Oral or intravenous ganciclovir treatment outside the study protocol~* Invasive fungal infection~* Participation in another investigational study~* Acute CMV infection or disease~* Anti-CMV therapy within 30 days before enrollment~* Uncontrolled diarrhea or malabsorption~* Allergic reaction to study drug~* Required use of prohibited medications~* Lactating women~* Pregnancy~* Renal failure~Inclusion Criteria for Phase II:~* Negative serial post transplant PCRs at day 75~* Negative bronchial cultures for CMV~* Adequate hematological and renal function at day 75~* IV ganciclovir for up to 2 weeks post operation and open label up to day 90~* Effective contraceptives~* Negative pregnancy~Exclusion Criteria Phase II:~* Renal failure~* Serious adverse events (SAE) related to study drug~* CMV disease (study endpoint)~* Withdraw consent for Phase II

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Valganciclovir 900 mg QD for 9 months post lung transplant.
- 2 (Type: PLACEBO_COMPARATOR): placebo for 9 months post lung transplant

Based on this trial design, predict the completion outcome and termination type (if applicable).